169 related articles for article (PubMed ID: 26528706)
1. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.
Roos A; Satterfield L; Zhao S; Fuja D; Shuck R; Hicks MJ; Donehower LA; Yustein JT
Br J Cancer; 2015 Nov; 113(9):1289-97. PubMed ID: 26528706
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling.
Liang GH; Liu N; He MT; Yang J; Liang ZJ; Gao XJ; Rahhal AH; He QY; Zhang HT; Zha ZG
J Cell Biochem; 2018 Jan; 119(1):948-959. PubMed ID: 28681940
[TBL] [Abstract][Full Text] [Related]
3. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.
Kurek KC; Del Mare S; Salah Z; Abdeen S; Sadiq H; Lee SH; Gaudio E; Zanesi N; Jones KB; DeYoung B; Amir G; Gebhardt M; Warman M; Stein GS; Stein JL; Lian JB; Aqeilan RI
Cancer Res; 2010 Jul; 70(13):5577-86. PubMed ID: 20530675
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
5. Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity.
Ozaki T; Sugimoto H; Nakamura M; Hiraoka K; Yoda H; Sang M; Fujiwara K; Nagase H
FEBS J; 2015 Jan; 282(1):114-28. PubMed ID: 25331851
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.
Sadikovic B; Thorner P; Chilton-Macneill S; Martin JW; Cervigne NK; Squire J; Zielenska M
BMC Cancer; 2010 May; 10():202. PubMed ID: 20465837
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a.
Li C; Zhang S; Qiu T; Wang Y; Ricketts DM; Qi C
Cancer Biol Ther; 2019; 20(4):413-422. PubMed ID: 30489194
[TBL] [Abstract][Full Text] [Related]
8. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
Posthumadeboer J; van Egmond PW; Helder MN; de Menezes RX; Cleton-Jansen AM; Beliën JA; Verheul HM; van Royen BJ; Kaspers GJ; van Beusechem VW
Oncotarget; 2012 Oct; 3(10):1169-81. PubMed ID: 23045411
[TBL] [Abstract][Full Text] [Related]
9. Matrix metallopeptidase 9 targeted by hsa-miR-494 promotes silybin-inhibited osteosarcoma.
Sun T; Cheung KSC; Liu ZL; Leung F; Lu WW
Mol Carcinog; 2018 Feb; 57(2):262-271. PubMed ID: 29068478
[TBL] [Abstract][Full Text] [Related]
10. A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells.
Shin MH; He Y; Marrogi E; Piperdi S; Ren L; Khanna C; Gorlick R; Liu C; Huang J
PLoS Genet; 2016 Feb; 12(2):e1005884. PubMed ID: 26925584
[TBL] [Abstract][Full Text] [Related]
11. MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2.
Xie Y; Sun W; Deng Z; Zhu X; Hu C; Cai L
Sci Rep; 2017 Oct; 7(1):13388. PubMed ID: 29042587
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
13. Wnt/β-Catenin Signaling Activates Expression of the Bone-Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types.
Vega OA; Lucero CMJ; Araya HF; Jerez S; Tapia JC; Antonelli M; Salazar-Onfray F; Las Heras F; Thaler R; Riester SM; Stein GS; van Wijnen AJ; Galindo MA
J Cell Biochem; 2017 Nov; 118(11):3662-3674. PubMed ID: 28370561
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-205 acts as a tumor suppressor in osteosarcoma via targeting RUNX2.
Zhang C; Long F; Wan J; Hu Y; He H
Oncol Rep; 2016 Jun; 35(6):3275-84. PubMed ID: 27035764
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma.
van der Deen M; Taipaleenmäki H; Zhang Y; Teplyuk NM; Gupta A; Cinghu S; Shogren K; Maran A; Yaszemski MJ; Ling L; Cool SM; Leong DT; Dierkes C; Zustin J; Salto-Tellez M; Ito Y; Bae SC; Zielenska M; Squire JA; Lian JB; Stein JL; Zambetti GP; Jones SN; Galindo M; Hesse E; Stein GS; van Wijnen AJ
J Biol Chem; 2013 Jul; 288(29):21307-21319. PubMed ID: 23720736
[TBL] [Abstract][Full Text] [Related]
16. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc.
Shen S; Yao T; Xu Y; Zhang D; Fan S; Ma J
Mol Cancer; 2020 Oct; 19(1):151. PubMed ID: 33106166
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo.
Yuan Q; Yu H; Chen J; Song X; Sun L
Exp Cell Res; 2018 Jan; 362(1):209-216. PubMed ID: 29155364
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway.
Jia F; Zhang Z; Zhang X
J Cell Biochem; 2019 Apr; 120(4):6420-6430. PubMed ID: 30484892
[TBL] [Abstract][Full Text] [Related]
19. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.
Martin JW; Chilton-MacNeill S; Koti M; van Wijnen AJ; Squire JA; Zielenska M
PLoS One; 2014; 9(5):e95843. PubMed ID: 24835790
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
Zhang Y; Duan G; Feng S
Biochem Biophys Res Commun; 2015 Apr; 459(3):367-73. PubMed ID: 25727016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
